Related Experiment Video
Updated: Jul 5, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
Published on: June 23, 2023
Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study
Zafar N Aliyev1, Nadir A Aliyev
1Narcological Dispensary of Ministry of Health of Azerbaijan Republic, Azerbaijan Republic.
Aims:
The aim of this study was to compare the efficacy and safety of valproate (Depakine-Chrono) versus placebo for the treatment of acute alcohol hallucinosis.
Methods:
10 days' randomized, double-blind, parallel study was conducted; 40 patients with an ICD-10 diagnosis of acute alcohol hallucinosis were randomized to valproate (Depakine-Chrono) 3000 mg/day (n = 20) or placebo (n = 20). The primary efficacy measure was the Clinical Global Improvement (CGI) and the Positive and Negative Syndrome Scale (PANSS), subscale for hallucinosis.
Results:
Valproate-treated patients demonstrated a greater improvement than placebo-treated patients in CGI (P < 0.001) and PANSS subscale for verbal hallucinosis (P < 0.001).
Conclusion:
Valproate is effective in the treatment of acute hallucinosis and is generally well tolerated.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Pharmaceutical Poisoning: Treatment Strategies
Psychosis and Antipsychotic Drugs: Overview
Antiepileptic Drugs: Glutamate Antagonists
Blind Procedures
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

